postmarketing pharmacovigilance practice at fda lanh green, pharm.d., m.p.h. office of surveillance...
DESCRIPTION
3 Office of Surveillance and Epidemiology (OSE) Mission: To evaluate product risks and promote the safe use of products by the American people Three Divisions Within OSE: Division of Drug Risk Evaluation (DDRE) Division of Medication Errors and Technical Support (DMETS) Division of Surveillance, Research and Communication Support (DSRCS)TRANSCRIPT
![Page 1: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/1.jpg)
Postmarketing Pharmacovigilance
Practice at FDA
Lanh Green, Pharm.D., M.P.H.Office of Surveillance and Epidemiology
June 21, 2006
![Page 2: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/2.jpg)
2
ObjectivesParticipants will gain knowledge on:• Postmarketing Safety Reporting
Regulation and Guidance• Suspected Adverse Drug Reaction
(SADR) Proposed Rule • Adverse Event Reporting System
(AERS)• Pharmacovigilance Practice at FDA
![Page 3: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/3.jpg)
3
Office of Surveillance and Epidemiology (OSE)
Mission: To evaluate product risks and promote the
safe use of products by the American people
Three Divisions Within OSE: • Division of Drug Risk Evaluation (DDRE) • Division of Medication Errors and Technical
Support (DMETS) • Division of Surveillance, Research and
Communication Support (DSRCS)
![Page 4: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/4.jpg)
4
Regulations • 310.305 - “Grandfathered” drugs (pre-1938)• 314.80 - Postmarketing drugs• 314.98- Generic drugs• 600.80- Biologics• No reporting requirements for OTC drugs
except for: • NDA-switched OTC products• Timed release dosage forms
21 CFR §310.502(a)(14)
![Page 5: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/5.jpg)
5
Serious Adverse Event (21 CFR 314.80)
• Death
• Life-threatening
• Hospitalization (initial or prolonged)• Disability• Congenital anomaly• Important medical events
![Page 6: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/6.jpg)
6
SADR Proposed Rule
• Codify ICH-developed guidelines toward global harmonization
• Increase quality of reports• Include medication errors • Timely acquisition, evaluation and
submission of safety information to promote public health
![Page 7: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/7.jpg)
7
Adverse Event Reporting System (AERS)
• Database originated in 1969 (SRS)• AERS implemented in Nov 1997
• Reports from Spontaneous Reporting System (SRS) migrated with mapping of COSTART to MedDRA
• More structured data, more detailed coding terminology, and greater capacity
• Electronic submissions (E2BM)
![Page 8: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/8.jpg)
8
Type of Reports
• Manufacturer Reports (mandatory): ~94% of reports – Health care professional, consumer, and
literature• 15-day reports - Foreign and domestic, serious
and unexpected (unlabeled) • Periodic reports - Quarterly for 3 years from
approval, then annually• Direct Reports (voluntary): ~6% of
reports – Health care professionals and consumers
![Page 9: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/9.jpg)
9
Limitations of Spontaneous Reports
• Passive surveillance system• Under-reporting exists• Quality of the reports is
variable/incomplete • Duplicate reporting occurs• Incidence rate cannot be determined
• Numerator is uncertain• Denominator can only be projected
![Page 10: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/10.jpg)
10
AERS Report Counts by Type: 1990 through 2005
050000100000150000200000250000300000350000400000450000500000
1990 1992 1994 1996 1998 2000 2002 2004
Direct15-dayPeriodic
![Page 11: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/11.jpg)
11
Pharmacovigilance Practice
• Applies to postmarketing activities• Involves all activities relating to
monitoring of product safety• Collection• Detection • Assessment of adverse effects or
risks of products
![Page 12: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/12.jpg)
12
Elements of AE Report
• Details of adverse event (AE)• Baseline patient status (age, co-morbid
conditions, concomitant medications, risk factors)
• Therapy details (dose, dates/duration of use) • Temporal relationship to drug • Dechallenge and rechallenge information• Method of diagnosis of AE• Clinical course of AE including outcomes• Lab results at baseline and during event
![Page 13: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/13.jpg)
13
Safety Evaluator Report Review• Main mission:
• To identify and assess previously unrecognized (unlabeled) serious adverse events
• Hands-on daily review of all 15-day and direct reports, monitors any safety issues including known adverse events
• Most intensive monitoring over first several years New Molecular Entities (NMEs) but continued over the drug's lifetime
![Page 14: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/14.jpg)
14
Principles of Case Evaluation
• Disease occurrence in expected time• Absence of symptoms prior to exposure• Positive dechallenge or rechallenge• Consistent with pharmacological effects• Consistent with known effects in the class• Event identified in clinical trials• Absence of alternative explanations
![Page 15: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/15.jpg)
15
Safety Signals
• New unlabeled adverse events• An observed increase in a labeled event
in its severity or specificity• New drug or food interactions• Newly identified at-risk population
![Page 16: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/16.jpg)
16
Identifying Safety Signals
• Depends on Good Reporting Practice to acquire quality case information to perform case-level review or case-series• Acquire complete information during initial
contacts and subsequent follow up• Entail a focused line of questioning
![Page 17: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/17.jpg)
17
Evaluating Potential Signals• Safety issue of interest identified• AERS search for related cases
• Use of MedDRA-cases coded at PT level• Customize search (broad or narrow) as
appropriate; can combine various MedDRA terms/levels into one search
• Case definition established; cases reviewed• Additional cases: Literature, WHO, foreign
regulators
![Page 18: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/18.jpg)
18
Data Mining
• Compares observed frequency of reports for specific drug/event combination to expected frequency of reports for that AE in entire AERS database (Empirical Baysian scores ≥ 2 worthy of investigation)
• Provides additional support to the case report evaluation and other safety information
![Page 19: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/19.jpg)
19
Epidemiologic Analysis
• Reporting Rates = cases/estimated usage (e.g., dispensed
prescriptions) • Comparison with background rates • Comparison to drugs within the same class • Comparison to drugs for similar indication • Interpretation difficult to make
• Additional study in longitudinal databases• Cooperative Agreements
• Review and analysis of Phase IV studies
![Page 20: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/20.jpg)
20
Communication Within CDER
• Open communication and collaboration with Office of New Drug (OND) and Office of Compliance
• Pre-approval Safety Conferences • Safety Conferences with OND • Safety question response– formal consult,
e-mail, or in person • Written communication – summary and analysis• Assistance in decision-making process for safety-
related regulatory action
![Page 21: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/21.jpg)
21
Potential Regulatory Action
• Labeling change • "Dear Health Care Professional" letter • Risk management plan/program
– Targeted Education and Outreach– Reminder Systems– Fail-Safe Systems
• Product withdrawal
![Page 22: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/22.jpg)
22
Guidance for Industry
• Risk Assessment (premarketing) http://www.fda.gov/cder/guidance/6357fnl.htm
• Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (postmarketing)http://www.fda.gov/cder/guidance/6359.OCC.htm
![Page 23: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/23.jpg)
23
Websites• Office of Surveillance and Epidemiology
http://www.fda.gov/cder/offices/ods/default.htm • Adverse Event Reporting System
http://www.fda.gov/cder/aers/default.htm– Reporting Regulations – Guidances– Updates
![Page 24: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/24.jpg)
24
Questions?
![Page 25: Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006](https://reader035.vdocuments.us/reader035/viewer/2022062223/5a4d1b507f8b9ab0599a7438/html5/thumbnails/25.jpg)
25
Objectives
Participants are knowledgeable with:• Postmarketing Safety Reporting
Regulation and Guidance• Suspected Adverse Drug Reaction
(SADR) Proposed Rule • Adverse Event Reporting System
(AERS)• Pharmacovigilance Practice at FDA